Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-085 capsules in adult NF1-mutant, unresectable plexiform neurofibromas (Phase II, single-arm, multicenter)
CTR20211967Phase 2Active
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib in plexiform neurofibroma (PN), neurofibromatosis type 1 (NF1), sponsored by Shanghai KeChow Pharmaceuticals. Started Nov 2021; status: active.
02
Drugs
tunlametinib
03
Conditions
plexiform neurofibroma (PN)neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on CTR20211967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211967.